Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASKA Pharmaceutical Co. Ltd.

www.aska-pharma.co.jp

Latest From ASKA Pharmaceutical Co. Ltd.

Deals Shaping The Medical Industry, March 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.

Deals BioPharmaceutical

Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline

Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.

Deals M & A

Deals Shaping The Medical Industry, February 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017

Deals BioPharmaceutical

Japan Delays Keytruda Pricing Amid PD-1 Cost Concerns

Regulatory authorities in Japan have put back the granting of a reimbursement price to Keytruda under the national health insurance system amid rising worries over the cost of new cancer immunotherapies, delaying the launch of the product for now.

Japan Reimbursement
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Teikoku Hormone Manufacturing Co. Ltd.
  • Grelan
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • ASKA Pharmaceutical Co. Ltd.
  • Senior Management
  • Takashi Yamaguchi, Pres.
  • Contact Info
  • ASKA Pharmaceutical Co. Ltd.
    Phone: (81) 3 548 48361
    2-5-1 Shibaura 2-chome
    Minato-ku, 108-8532
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register